SAN DIEGO, March 24 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a company focused on the discovery and development of small- molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout, today reported significant accomplishments in 2007, provided key milestones in 2008 for its clinical development programs, announced 2007 fourth quarter and full-year financial results and provided financial guidance for 2008.
"During 2007, we made significant strides in establishing a solid
corporate foundation on which our future successes will be built," said
Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "We assembled
a proven management team and a group of key expert advisors; we added depth
to our pipeline through the discovery of an exciting new product
opportunity in gout; and we continued to make progress with our HIV, cancer
and inflammatory disease programs."
-- Reported positive preliminary data from a Phase 2a proof-of-concept
trial of RDEA806 in patients with HIV;
-- Initiated a new clinical development program, stemming from our
RDEA806 research, directed toward the treatment of gout;
-- Initiated a Phase 1 trial of RDEA119 in patients with advanced cancer;
-- Completed a first-in-human micro-dosing study of RDEA436, a second
generation MEK inhibitor for the treatment of cancer and inflammatory
diseases and, based on an encouraging pharmacokinetic profile,
nominated it as a development candidate;
-- Completed a $40 million private placement;
-- Established two scientific advisory boards to guide the inflammatory
disease and H
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved